Skip to content

Comparison of Intranasal Ketamine Spray and Intravenous Morphine in Reducing Headache in Patients with Headache

Comparison of Intranasal Ketamine Spray and Intravenous Morphine in Reducing Headache in Patients with Headache; A Randomized Double-Blinded Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200602047633N2
Enrollment
110
Registered
2023-08-16
Start date
2021-09-23
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Headache. Other headache syndromes

Interventions

Intervention 1: Intervention group: 50 patients who were treated with intranasal ketamine at a dose of 0.7 mg/kg (the maximum dose was considered 40 mg) in the form of three puffs inside each nostril

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Trauma patients with trauma pain with a pain score greater than 4 Age over 14 years Age less than 65 years

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The time to start responding to treatment. Timepoint: Measurement of pain score at the beginning of the study (before the intervention) and 5, 10, 15, 30 and 60 minutes after the start of treatment. Method of measurement: Visual Analog Scale (VAS).

Secondary

MeasureTime frame
Creating analgesia which patient's intensity pain goes below than 5. Timepoint: Measurement of pain score at the beginning of the study (before the intervention) and 5, 10, 15, 30 and 60 minutes after the start of treatment. Method of measurement: Visual analog scale (VAS).;The rate of complications in both groups. Timepoint: At the end of the study. Method of measurement: Calculate the number.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Soheila Azimi

Yazd University of Medical Sciences

soheila.azimi1987@gmail.com+98 35 3828 2682

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026